<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36108609</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1934-6069</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>Cell host &amp; microbe</Title><ISOAbbreviation>Cell Host Microbe</ISOAbbreviation></Journal><ArticleTitle>A counterintuitive antibody cocktail disrupts coxsackievirus.</ArticleTitle><Pagination><StartPage>1194</StartPage><EndPage>1195</EndPage><MedlinePgn>1194-1195</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chom.2022.08.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1931-3128(22)00409-7</ELocationID><Abstract><AbstractText>Utilizing monoclonal antibodies to prevent and treat infectious diseases has been accelerated by the COVID-19 pandemic. In this issue of Cell Host &amp; Microbe, Zheng et al. show how a three-monoclonal-antibody cocktail, that defies conventions of "rational design" for a therapeutic agent, functions cooperatively to disrupt coxsackievirus virions.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zost</LastName><ForeName>Seth J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogt</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Infectious Diseases, and Department of Microbiology &amp; Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA. Electronic address: mrvogt@unc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AI156125</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Host Microbe</MedlineTA><NlmUniqueID>101302316</NlmUniqueID><ISSNLinking>1931-3128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Cell Host Microbe. 2022 Sep 14;30(9):1279-1294.e6. doi: 10.1016/j.chom.2022.08.001</RefSource><PMID Version="1">36002016</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests M.R.V. is a paid consultant for IDBiologics, Inc. and is co-inventor on a patent application for anti-enterovirus D68 human monoclonal antibodies filed by Vanderbilt University. S.J.Z. is a co-inventor on patent applications for anti-SARS-CoV-2 human monoclonal antibodies filed by Vanderbilt University.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36108609</ArticleId><ArticleId IdType="pmc">PMC9472682</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2022.08.010</ArticleId><ArticleId IdType="pii">S1931-3128(22)00409-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. doi: 10.1126/science.abd0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0831</ArticleId><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P., Nirula A., Heller B., Gottlieb R.L., Boscia J., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N. Engl. J. Med. 2021;384:229–237. doi: 10.1056/nejmoa2029849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2029849</ArticleId><ArticleId IdType="pmc">PMC7646625</ArticleId><ArticleId IdType="pubmed">33113295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilchuk P., Murin C.D., Cross R.W., Ilinykh P.A., Huang K., Kuzmina N., Borisevich V., Agans K.N., Geisbert J.B., Zost S.J., et al. Pan-ebolavirus protective therapy by two multifunctional human antibodies. Cell. 2021;184:5593–5607.e18. doi: 10.1016/j.cell.2021.09.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.09.035</ArticleId><ArticleId IdType="pmc">PMC8716180</ArticleId><ArticleId IdType="pubmed">34715022</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson S., Oliver C., Prince G., Hemming V., Pfarr D., Wang S., Dormitzer M., O'Grady J., Koenig S., Tamura J., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997;176:1215–1224. doi: 10.1086/514115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/514115</ArticleId><ArticleId IdType="pubmed">9359721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulangu S., Dodd L.E., Davey R.T., Jr., Tshiani Mbaya O., Proschan M., Mukadi D., Lusakibanza Manzo M., Nzolo D., Tshomba Oloma A., Ibanda A., et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N. Engl. J. Med. 2019;381:2293–2303. doi: 10.1056/nejmoa1910993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1910993</ArticleId><ArticleId IdType="pmc">PMC10680050</ArticleId><ArticleId IdType="pubmed">31774950</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Veyer D., Baidaliuk A., Staropoli I., Guivel-Benhassine F., Rajah M.M., Planchais C., Porrot F., Robillard N., Puech J., et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–280. doi: 10.1038/s41586-021-03777-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan L.A., Errico J.M., Halfmann P.J., Zost S.J., Crowe J.E., Jr., Purcell L.A., Kawaoka Y., Corti D., Fremont D.H., Diamond M.S. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28:490–495. doi: 10.1038/s41591-021-01678-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01678-y</ArticleId><ArticleId IdType="pmc">PMC8767531</ArticleId><ArticleId IdType="pubmed">35046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt M.R., Fu J., Kose N., Williamson L.E., Bombardi R., Setliff I., Georgiev I.S., Klose T., Rossmann M.G., Bochkov Y.A., et al. Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease. Sci Immunol. 2020;5:eaba4902. doi: 10.1126/sciimmunol.aba4902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aba4902</ArticleId><ArticleId IdType="pmc">PMC7418079</ArticleId><ArticleId IdType="pubmed">32620559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q., Zhu R., Yin Z., Xu L., Sun H., Yu H., Wu Y., Jiang Y., Huang Q., Huang Y., et al. Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail. Cell Host Microbe. 2022;30 doi: 10.1016/j.chom.2022.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.08.001</ArticleId><ArticleId IdType="pubmed">36002016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost S.J., Gilchuk P., Case J.B., Binshtein E., Chen R.E., Nkolola J.P., Schafer A., Reidy J.X., Trivette A., Nargi R.S., et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584:443–449. doi: 10.1038/s41586-020-2548-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2548-6</ArticleId><ArticleId IdType="pmc">PMC7584396</ArticleId><ArticleId IdType="pubmed">32668443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>